Equities research analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to report ($0.74) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Crispr Therapeutics’ earnings. The lowest EPS estimate is ($0.77) and the highest is ($0.71). Crispr Therapeutics posted earnings of ($0.40) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 85%. The firm is scheduled to report its next earnings report on Friday, March 9th.

On average, analysts expect that Crispr Therapeutics will report full-year earnings of ($2.46) per share for the current financial year, with EPS estimates ranging from ($2.49) to ($2.43). For the next year, analysts expect that the business will report earnings of ($3.06) per share, with EPS estimates ranging from ($3.08) to ($3.04). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.02). The company had revenue of $2.39 million for the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. Crispr Therapeutics’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.77) earnings per share.

CRSP has been the topic of several research analyst reports. Barclays restated a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a research report on Friday, September 8th. Oppenheimer restated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, December 21st. Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Sunday, December 10th. BidaskClub lowered shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Finally, SunTrust Banks reiterated a “hold” rating and issued a $16.00 price objective on shares of Crispr Therapeutics in a research report on Friday, November 10th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $22.38.

In related news, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $18.98, for a total value of $21,114,225.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas Woiwode sold 1,700 shares of the business’s stock in a transaction dated Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the completion of the transaction, the director now directly owns 8,218 shares of the company’s stock, valued at approximately $166,085.78. The disclosure for this sale can be found here. Insiders sold a total of 1,950,654 shares of company stock worth $37,126,688 over the last quarter. Insiders own 39.98% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in Crispr Therapeutics by 459.7% in the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after purchasing an additional 6,560 shares during the last quarter. Capital Investment Advisory Services LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter valued at about $193,000. Ark Investment Management LLC acquired a new position in shares of Crispr Therapeutics during the 2nd quarter valued at about $206,000. Moloney Securities Asset Management LLC acquired a new position in shares of Crispr Therapeutics during the 3rd quarter valued at about $235,000. Finally, Vanguard Group Inc. acquired a new position in shares of Crispr Therapeutics during the 2nd quarter valued at about $273,000. 24.52% of the stock is owned by hedge funds and other institutional investors.

Shares of Crispr Therapeutics (CRSP) traded up $0.14 during midday trading on Wednesday, hitting $21.29. 390,800 shares of the company’s stock traded hands, compared to its average volume of 156,438. The stock has a market cap of $873.30 and a price-to-earnings ratio of -66.53. Crispr Therapeutics has a 52 week low of $11.63 and a 52 week high of $25.00.

COPYRIGHT VIOLATION WARNING: This news story was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://theolympiareport.com/2017/12/27/brokerages-expect-crispr-therapeutics-ag-crsp-to-announce-0-74-earnings-per-share.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.